Sökning: "CAR T-cell therapy"

Visar resultat 1 - 5 av 8 avhandlingar innehållade orden CAR T-cell therapy.

  1. 1. Improvement of adoptive T-cell therapy for Cancer

    Författare :Chuan Jin; Magnus Essand; Ola Winqvist; Uppsala universitet; []
    Nyckelord :MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; CAR T-cell therapy; AEP expansion protocol; scaffold matrix attachment region; non-integrating lentivirus; H. pylori Neutrophil-activating protein; allogeneic DCs; Klinisk immunologi; Clinical Immunology;

    Sammanfattning : Cancer immunotherapy has recently made remarkable clinical progress. Adoptive transfer of T-cells engineered with a chimeric antigen receptor (CAR) against CD19 has been successful in treatment of B-cell leukemia. LÄS MER

  2. 2. The Multiple Faces of Genetically-Modified T Cells : Potential Applications in Therapy

    Författare :Victoria Hillerdal; Magnus Essand; Johanna Olweus; Uppsala universitet; []
    Nyckelord :MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; cancer immunotherapy; genetically engineered T cells; chimeric antigen receptor; T cell receptor; antigen-specific T cells; immunotherapy; Immunologi; Immunology; Klinisk immunologi; Clinical Immunology;

    Sammanfattning : In this PhD thesis the potential of T-cells as therapy for disease are explored. The applications of genetically modified T-cells for treatment of cancer and autoimmune disease; the functionality and optimal activation of T-cells are discussed. LÄS MER

  3. 3. CD19-targeting CAR T Cells for Treatment of B Cell Malignancies : From Bench to Bedside

    Författare :Hannah Karlsson; Angelica Loskog; Karl-Johan Malmberg; Uppsala universitet; []
    Nyckelord :NATURAL SCIENCES; NATURVETENSKAP; NATURVETENSKAP; NATURAL SCIENCES; chimeric antigen receptors; CAR T cells; T cell therapy; immunotherapy; CD19; Bcl-2 family inhibitors; B cell malignancies; Klinisk immunologi; Clinical Immunology;

    Sammanfattning : Immunotherapy for cancer is a young research field progressing at high speed. The first chimera of an antibody and a signaling chain was designed by Zelig Eshhar and was later further developed to enhance existing T cell therapy by combining a single-chain fragment of an antibody with the CD3 zeta chain of the TCR complex. LÄS MER

  4. 4. Novel immunotherapies for metastatic melanoma - from mouse models towards clinical trials

    Författare :Elin Forsberg; Göteborgs universitet; Göteborgs universitet; Gothenburg University; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Metastatic melanoma; uveal melanoma; patient-derived xenograft; immune-humanized mouse model; immunotherapy; adoptive T cell therapy; tumor-infiltrating lymphocytes; chimeric antigen receptor T CAR-T cells;

    Sammanfattning : Immunotherapies including checkpoint blockade and adoptive T cell transfer (ACT) show great promise for the treatment of melanoma, with long-term effects in some patients. However, around half of the patients with metastatic malignant melanoma will not be cured with available therapies today, and these patients require other treatment strategies. LÄS MER

  5. 5. Cancer Immunotherapy : Oncolytic viruses and CAR-T cells

    Författare :Jing Ma; Di Yu; Magnus Essand; Mia Phillipson; Mohanraj Ramachandran; Karl-Johan Malmberg; Uppsala universitet; []
    Nyckelord :MEDICAL AND HEALTH SCIENCES; MEDICIN OCH HÄLSOVETENSKAP; MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Cancer immunotherapy; Oncolytic viruses; chimeric antigen receptor CAR -T cells; Helicobacter pylori Neutrophil Activating Protein;

    Sammanfattning : Various forms of cancer immunotherapy have developed rapidly with improved survival and quality of life for cancer patients. Cancer immunotherapy aims to educate the patient’s immune system to eliminate cancer cells, including immune checkpoint inhibitors (ICIs), adoptive cell transfer (mostly T cells), oncolytic viruses (OVs) and cancer vaccines. LÄS MER